FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the feasibility of Ixabepilone (4 cycles) administered
every 14 days with the support of G-CSF sequentially to the combination of Fluorouracil,
Epirubicin and Cyclophosphamide (4 cycles) administered every 14 days with the support of
G-CSF.
To evaluate the efficacy (in terms of pathologic Complete Responses in the breast and in the
axilla), the dose reduction rate, the median treatment delay and the discontinuation rate due
to toxicity of the regimen.